| Patient | Zora Neale Hurston |
|---|---|
| Date of birth | 1959-01-07 |
| Identifiers | MRN HR-ML040-SYN; SSN (made up) 000-40-6213 |
| Document date | 2026-03-23 |
| Author | Lorraine Abernathy-Osei, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week review: blood pressure, echocardiogram and cardiology consultation. [S]
Ms. Hurston returns two weeks after intake and is seen the same day by Dr. Okafor-Whitfield of cardiology after her echocardiogram this morning. The 24-hour ambulatory recording before her first doses averaged 158/96 mmHg (daytime 163/99, night 149/90), with no fall in pressure at night, which confirms stage 2 hypertension. She started chlorthalidone 12.5 mg and amlodipine 5 mg the next morning; her home readings over the past week average 146/88. The morning headaches have gone. She is still breathless on one flight of stairs and her ankles swell a little by evening. She has had no lightheadedness, cramps or palpitations. The echocardiogram shows a preserved ejection fraction with thick heart walls and stiff filling. She met the community health worker last week: her SNAP application is in, and a SHINE counselor will see her on Thursday about drug coverage. [S]
| Element | Detail |
|---|---|
| Ambulatory blood pressure | 24-hour mean 158/96 mmHg; daytime 163/99; night 149/90 (non-dipping) |
| Home blood pressure on treatment | Average 146/88 mmHg over seven days |
| Symptoms | Headaches gone; breathless on one flight of stairs; mild evening ankle swelling |
| Echocardiogram | Ejection fraction 62%; concentric left ventricular hypertrophy; grade II diastolic dysfunction |
| KCCQ-12 | 54 |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Positive | Breathless on one flight of stairs; mild evening ankle swelling; no chest pain, palpitations, orthopnea or night breathlessness |
| Neurological | Negative | Headaches resolved; no weakness, numbness, speech or vision change |
| Genitourinary | Negative | Passing more urine in the mornings; no burning |
| Musculoskeletal | Negative | No cramps |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amlodipine 5 mg oral tablet, one tablet every morning | One tablet every morning | Oral route | 2026-03-09 | active | S |
| Chlorthalidone 25 mg oral tablet, one-half tablet (12.5 mg) every morning | One-half tablet every morning | Oral route | 2026-03-09 | active | S |
| Dapagliflozin 10 mg oral tablet, one tablet daily; pause on days of vomiting, diarrhea or not eating or drinking | One tablet daily, with sick-day rules | Oral route | 2026-03-23 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-23 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-23 | Body height | 165 | cm | S |
| 2026-03-23 | Body weight | 83.4 | kg | S |
| 2026-03-23 | Body mass index (BMI) [Ratio] | 30.6 | kg/m2 | S |
| 2026-03-23 | Systolic blood pressure | 150 | mm[Hg] | S |
| 2026-03-23 | Diastolic blood pressure | 90 | mm[Hg] | S |
| 2026-03-23 | Heart rate | 78 | /min | S |
| 2026-03-23 | Respiratory rate | 16 | /min | S |
| 2026-03-23 | Body temperature | 36.6 | Cel | S |
| 2026-03-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-23 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-23 | Potassium [Moles/volume] in Serum or Plasma | 3.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-23 | Creatinine [Mass/volume] in Serum or Plasma | 0.94 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-03-23 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 67 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-03-23 | Glucose [Mass/volume] in Serum or Plasma | 98 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-03-23 | Magnesium [Mass/volume] in Serum or Plasma | 1.9 | mg/dL | 1.6-2.6 mg/dL | Normal | S |
| 2026-03-23 | Left ventricular Ejection fraction | 62 | % | 50-70% | Normal | S |
| 2026-03-23 | Left atrial End-systolic volume (by US.2D+Calculated by biplane method of disks)/Body surface area | 38 | mL/m2 | <=34 mL/m² | High | S |
| 2026-03-23 | Heart valve E velocity/Annulus E wave by US | 15 | {ratio} | <=14 | High | S |
| 2026-03-23 | Overall summary score [KCCQ-12] | 54 | {score} | S |
Vital signs recorded on 2026-03-23; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 150/90, pulse 78; weight 83.4 kg, down 0.8 kg |
| Neck | Jugular venous pressure not raised; no carotid bruits |
| Cardiovascular | Regular rhythm; sustained apical impulse; S4; no murmur |
| Respiratory | Clear |
| Extremities | Trace ankle edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Very high blood pressure at intake (178/104 and 174/102 mmHg) with morning headaches for two months, without signs of a hypertensive emergency; not previously diagnosed; ambulatory monitoring to confirm | resolved | confirmed | R03.0 | S — Synthetic presenting problem, resolved when ambulatory monitoring and the echocardiogram established the diagnosis at the second visit. Not a claim about her real blood pressure. |
| Breathlessness on exertion for three months (walking to the school, carrying groceries) with mild ankle swelling by evening; cause to be determined | resolved | confirmed | R06.09 | S — Synthetic presenting problem, resolved into the heart failure diagnosis at the second visit. |
| Hypertensive heart disease with heart failure: stage 2 hypertension confirmed by 24-hour ambulatory monitoring (mean 158/96 mmHg, non-dipping at night), with concentric left ventricular hypertrophy on ECG and echocardiogram; synthetic modern episode linked to the hypertensive heart disease recorded as her cause of death | active | confirmed | I11.0 | S — Synthetic modern diagnosis made at the second visit; the 1960 cause of death remains D. |
| Heart failure with preserved ejection fraction (ejection fraction 62%), NYHA class II, with grade II diastolic dysfunction and an enlarged left atrium | active | confirmed | I50.32 | S — Synthetic modern diagnosis confirmed by echocardiogram and cardiology at the second visit. |
| Food insecurity: food runs short at the end of most months (Hunger Vital Sign positive) | active | confirmed | Z59.41 | S — Synthetic social need anchored to her documented poverty. |
| Low and irregular income from substitute teaching and newspaper writing, with Original Medicare but no drug coverage; medicine costs a barrier | active | confirmed | Z59.6 | S — Synthetic social need anchored to her documented low income in the 1950s. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure in the clinic (seated, average of two readings, large cuff) | Every visit | Completed today | 150/90 mmHg |
| Examination | Out-of-office blood pressure (ambulatory at diagnosis; home readings when treatment changes) | At diagnosis and with each treatment change | Completed today | Ambulatory 24-hour mean 158/96 (non-dipping) before treatment; home average 146/88 on treatment |
| Examination | Weight, volume status (jugular venous pressure, edema, lungs) and NYHA class | Every visit | Completed today | 83.4 kg; jugular venous pressure not raised; trace ankle edema; lungs clear; NYHA II |
| Laboratory | Metabolic panel (sodium, potassium, creatinine and eGFR) and magnesium | One to two weeks after starting or changing a diuretic, SGLT2 inhibitor or MRA; then every three to six months | Completed today | Two weeks after chlorthalidone: sodium 138, potassium 3.6, creatinine 0.94 mg/dL (eGFR 67), magnesium 1.9 |
| Imaging | ECG and echocardiogram | At diagnosis; repeat only with unexplained clinical change | Completed today | ECG at intake: left ventricular hypertrophy, sinus rhythm. Echocardiogram today: ejection fraction 62%, left atrial volume index 38 mL/m2, E/e' 15, concentric hypertrophy |
| Survey | KCCQ-12 heart failure health status | At diagnosis, then every three to six months | Completed today | 54 at diagnosis |
| Laboratory | Lipid panel | Four to twelve weeks after starting a statin; then yearly | Ordered | LDL 132 mg/dL at intake; atorvastatin started today; panel due in four to twelve weeks |
| Laboratory | Urine albumin-to-creatinine ratio | Yearly | Up to date | 22 mg/g at intake |
| Laboratory | Hemoglobin A1c | Yearly | Up to date | 5.6% at intake |
| Survey | Depression screen (PHQ-2, then PHQ-9 if positive) | Yearly | Up to date | PHQ-2 1 at intake |
| Examination | Eye examination for hypertensive retinopathy | Yearly | Up to date | Arteriolar narrowing and nicking without hemorrhage at intake; dilated examination to be arranged |
| Self-management | Self-care: daily weights, less salt, sick-day rules and the BE FAST stroke signs | Every visit | Completed today | Scale at home; written weight plan; sick-day rules for dapagliflozin; BE FAST card reviewed |
| Medication safety | Medicine costs and coverage (generics, 90-day fills, patient assistance, Extra Help, Medicare Savings Program) | Every visit | Completed today | Generics in 90-day fills; patient assistance for dapagliflozin; SHINE appointment this week |
| Self-management | Food access | Every visit | Completed today | SNAP application submitted with the community health worker |
| Referral | Cardiology consultation | At diagnosis | Completed today | Seen by Dr. Okafor-Whitfield today |
Goal progress:
Immunizations given today: Pneumococcal conjugate vaccine PCV20 [S]
Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction (2023); CMID: Clinical Monitoring Intelligence Database, hypertension and heart failure monographs (2026); Signs and Symptoms of Stroke (2026); Help with drug costs (Extra Help) (2026); SHINE (Serving Health Insurance Needs of Elders), Florida's State Health Insurance Assistance Program (2026)
Follow-up: Two-week review with a metabolic panel. Call for lightheadedness, a weight gain beyond the plan, or breathlessness at rest; call 911 for any BE FAST sign or chest pain. Next scheduled visit 2026-04-06: two-week review after dapagliflozin: metabolic panel, blood pressure and potassium, and benefits applications. [S]